Clinical Pearls -- NCCN 2013 Oncology Pharmacy Best Practices Webinar Series: New and Emerging Drugs and Biologics in Oncology (CML)
Pharmacists are important to the clinical decision-making process, both at the individual patient level and the drug use policy level. At the individual patient level, the oncology multidisciplinary team typically includes a clinical pharmacist who specializes in oncology. Furthermore, pharmacists dispensing chemotherapy require the clinical knowledge and expertise to effectively assess the appropriateness of therapy (i.e., for indication, dosing, etc.) and monitor the patient for adverse effects. Pharmacists also must be knowledgeable about specific drugs to be able to effectively counsel a patient regarding medications. At the policy level, pharmacists are actively involved in the formation of drug use policy though their participation on Pharmacy & Therapeutics committees for hospitals and managed care organizations. Often, the pharmacist on the committee performs the literature review and writes the policy for the committee to approve.
This educational program is designed to meet the educational needs of pharmacists.
Following this activity, participants should be able to:
- Identify new and emerging agents in oncology
- Describe the clinical implications of these agents and their impact on the current standard of oncology care
- Provide recommendations to facilitate a comprehensive approach to treatment decisions relative to new therapies
Hillary A. Prescott, PharmD, BCOP
The University of Texas MD Anderson Cancer Center
- 0.25 Participation
- 0.25 Pharmacist